A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Lurasidone (Primary)
- Indications Bipolar I disorders; Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 19 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 30 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 28 Jul 2012 Additional lead trial centre added as reported by European Clinical Trials Database record.